7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 
      
    		                           
      cash flows from operating activities
    		                           
      net income
    		-34,000,000 11,000,000 67,000,000 -8,000,000 364,000,000 -50,000,000 32,000,000 -141,000,000 -1,096,000,000 -97,000,000 103,000,000 -55,000,000 -49,000,000 -22,000,000 48,000,000 -97,000,000 -104,000,000 -210,000,000 -61,000,000 -322,800,000 -135,000,000 -53,200,000 -49,100,000 -9,500,000 10,000,000 35,900,000 31,500,000 
      adjustments to reconcile net income to cash flows from operating activities:
    		                           
      depreciation and amortization
    		176,000,000 169,000,000 161,000,000 164,000,000 170,000,000 162,000,000 166,000,000 171,000,000 173,000,000 177,000,000 173,000,000 168,000,000 167,000,000 171,000,000 176,000,000 174,000,000 170,000,000 170,000,000 202,000,000 222,200,000 132,300,000 80,900,000 81,500,000 83,400,000 78,700,000 69,300,000 83,100,000 
      stock-based compensation expense
    		17,000,000 20,000,000 15,000,000 15,000,000 15,000,000 14,000,000 11,000,000 15,000,000 10,000,000 9,000,000 12,000,000 15,000,000 13,000,000 17,000,000 14,000,000 18,000,000 17,000,000 16,000,000 15,000,000 16,600,000 11,700,000 8,300,000 11,100,000 12,700,000 14,800,000 14,200,000 7,700,000 
      asset impairment and write-down charges
    		   5,000,000 15,000,000   27,000,000    -6,000,000 0 59,000,000 28,000,000 5,000,000 56,000,000           
      gain on divestiture
    		   0         0               
      sold portion of royalty revenue
    		-6,000,000                           
      interest on liability for sale of future revenue
    		13,000,000                           
      changes in operating assets and liabilities, net of acquisitions and divestitures
    		59,000,000 52,000,000 -237,000,000  248,000,000 22,000,000 -177,000,000                     
      other non-cash operating activities
    		-30,000,000 -18,000,000 -10,000,000 57,000,000 -15,000,000 -9,000,000 -30,000,000 17,000,000 -20,000,000 10,000,000 2,000,000 -13,000,000 -10,000,000 8,000,000 13,000,000 -1,000,000   10,000,000 -28,900,000 44,000,000 5,100,000 -500,000 7,300,000 2,600,000 -13,200,000 -9,400,000 
      net cash from operating activities
    		219,000,000 237,000,000 -4,000,000 177,000,000 162,000,000 200,000,000 2,000,000 157,000,000 198,000,000 61,000,000 -145,000,000 13,000,000 189,000,000 312,000,000 -62,000,000 223,000,000 89,000,000 149,000,000 22,000,000 -92,900,000 -111,700,000 159,300,000 4,300,000 126,300,000 39,600,000 52,600,000 5,600,000 
      capex
    		-92,000,000 -57,000,000 -65,000,000 -47,000,000 -42,000,000 -34,000,000 -24,000,000 0 -33,000,000 0 -20,000,000 0 -26,000,000 -26,000,000 -19,000,000 0 0 0 -18,000,000 0 0 0 -12,600,000 0 -34,200,000 -23,800,000 -28,000,000 
      free cash flows
    		127,000,000 180,000,000 -69,000,000 130,000,000 120,000,000 166,000,000 -22,000,000 157,000,000 165,000,000 61,000,000 -165,000,000 13,000,000 163,000,000 286,000,000 -81,000,000 223,000,000 89,000,000 149,000,000 4,000,000 -92,900,000 -111,700,000 159,300,000 -8,300,000 126,300,000 5,400,000 28,800,000 -22,400,000 
      cash flows from investing activities
    		                           
      net purchases of property and equipment and software
    		-92,000,000 -57,000,000 -65,000,000 -47,000,000 -42,000,000 -34,000,000 -24,000,000  -33,000,000                   
      proceeds from divestitures
    		0 0 9,000,000                         
      other investing activities
    		-9,000,000 1,000,000 -2,000,000  0   6,000,000 0 -1,000,000 -1,000,000 1,000,000 -2,000,000 -4,000,000 -3,000,000 0 -1,000,000 0 -7,000,000 900,000 -6,700,000 -900,000 -400,000 36,800,000 -16,000,000 -25,200,000 -500,000 
      net cash from investing activities
    		-101,000,000 -56,000,000 -58,000,000 -90,000,000 1,244,000,000 -33,000,000 37,000,000 -35,000,000 -36,000,000 -43,000,000 -55,000,000 -76,000,000 -37,000,000 -37,000,000 -29,000,000 -74,000,000 -441,000,000 -25,000,000 10,000,000 -73,300,000 -4,696,900,000 10,600,000 -19,600,000 -74,300,000 -83,000,000 -49,000,000 -28,500,000 
      cash flows from financing activities
    		                           
      proceeds from revolving credit facility
    		0 0 125,000,000 0 0 0 50,000,000 0 100,000,000 50,000,000 200,000,000 0 0 500,000,000 63,000,000             
      repayments of revolving credit facility
    		0 0 -125,000,000 0 0 -200,000,000 -50,000,000 -97,000,000    0 -75,000,000 -575,000,000 -163,000,000             
      proceeds from securitization facility
    		0 0 125,000,000 0 0 120,000,000 50,000,000 0                    
      repayments of securitization facility
    		0 -85,000,000 -40,000,000 -25,000,000 -120,000,000 0 -50,000,000 -28,000,000                    
      proceeds from issuance of long-term debt
    		   0        0 0   0    250,000,000 4,475,000,000 0 79,200,000     
      repayments of long-term borrowings
    		-188,000,000 -361,000,000 -13,000,000 -13,000,000 -1,562,000,000 -12,000,000 -13,000,000 -14,000,000 -356,000,000 -13,000,000 -19,000,000 -70,000,000 -79,000,000 -439,000,000 -89,000,000             
      proceeds from sale of future revenue, net of transaction costs
    		0                           
      other financing activities
    		35,000,000 0 -20,000,000 6,000,000 -8,000,000 -1,000,000 -14,000,000 0 -1,000,000 2,000,000 -7,000,000 1,000,000 0 -6,000,000 -11,000,000 -12,000,000 0 0 -17,000,000 -1,000,000 -1,000,000 -1,400,000 -12,800,000 -100,000 300,000 1,900,000 -500,000 
      net cash from financing activities
    		-153,000,000 -156,000,000 52,000,000 -32,000,000 -1,340,000,000 -93,000,000 -27,000,000 -139,000,000 -157,000,000 39,000,000 174,000,000 -84,000,000 -169,000,000 -96,000,000 -200,000,000 44,000,000 231,000,000 -67,000,000 2,000,000 -18,300,000 4,068,300,000 7,300,000 896,600,000 -6,200,000 -48,800,000 89,700,000 -339,500,000 
      effect of exchange rate changes on cash and cash equivalents
    		1,000,000 27,000,000 29,000,000 -77,000,000 8,000,000 -3,000,000 -19,000,000 0 -3,000,000 -8,000,000 -1,000,000 32,000,000 -30,000,000 -14,000,000 -5,000,000 -8,000,000 -6,000,000 8,000,000 -25,000,000 19,300,000 9,100,000 7,500,000 -9,300,000 -21,000,000 15,900,000 2,700,000 -14,500,000 
      net increase in cash and cash equivalents
    		-34,000,000 52,000,000 19,000,000 -22,000,000 74,000,000   -17,000,000 2,000,000     165,000,000 -296,000,000             
      cash and cash equivalents – beginning of period
    		0 0 468,000,000  0 0 352,000,000  0                   
      cash and cash equivalents – end of period
    		-34,000,000 52,000,000 487,000,000  74,000,000 71,000,000 345,000,000  2,000,000                   
      supplemental disclosure of non-cash investing and financing activities:
    		                           
      right-of-use assets obtained in exchange for new finance lease liability
    		-8,000,000                           
      goodwill impairment
    		       0                    
      deferred income taxes
    		          2,000,000 -21,000,000 4,000,000 -29,000,000 -11,000,000             
      loss on extinguishment of debt
    		           1,000,000 2,000,000               
      proceeds from interest rate swap settlements
    		   0    0    0 75,000,000               
      other changes in operating assets and liabilities, net of acquisitions and divestitures:
    		                           
      receivables
    		                           
      inventories
    		                           
      other assets
    		                           
      accounts payable and other liabilities
    		                           
      purchases of intangible assets
    		   -6,000,000    0 0 0 -14,000,000 -2,000,000 -10,000,000   -3,000,000 -1,000,000 -1,000,000 -33,000,000         
      cash paid for acquisitions
    		   -36,000,000 0 0 -5,000,000  -3,000,000 0 -16,000,000                 
      proceeds from aqua business divestiture
    		                           
      proceeds from sale of shawnee and speke facilities
    		     0 66,000,000                     
      funding related to construction of corporate headquarters
    		                           
      cash and cash equivalents at january 1
    		          345,000,000  0 0 638,000,000             
      cash and cash equivalents at december 31
    		                           
      proceeds from business divestitures
    		                           
      proceeds from previous sale of shawnee and speke facilities
    		                           
      net decrease in cash and cash equivalents
    		      -7,000,000    -27,000,000                 
      inventory fair value step-up amortization
    		          1,000,000     0 1,000,000 1,000,000 62,000,000         
      other changes in operating assets and liabilities
    		                          -127,600,000 
      purchases of property and equipment and software
    		                           
      cash paid for acquisitions, net of cash acquired
    		               0 -415,000,000 0 73,000,000 0    0    
      changes in operating assets and liabilities, net of acquisitions
    		        27,000,000 -34,000,000 -439,000,000      -53,000,000 -7,000,000 -183,000,000         
      loss on sale of assets
    		          1,000,000  2,000,000               
      net purchases of property and equipment
    		          -20,000,000  -26,000,000 -26,000,000 -19,000,000    -18,000,000    -12,600,000  -34,200,000 -23,800,000 -28,000,000 
      purchases of software
    		          -4,000,000 -11,000,000 -10,000,000 -6,000,000 -7,000,000 -22,000,000 1,000,000 -7,000,000 -5,000,000 -28,500,000 -88,200,000 -27,800,000 -31,800,000     
      cash and cash equivalents at march 31
    		          318,000,000    342,000,000             
      gain on sale of assets
    		              1,000,000     0 0 -47,500,000 -3,800,000     
      gain on divestitures
    		               -1,000,000    -300,000        
      purchases of property and equipment
    		                           
      disposals of property and equipment
    		                           
      divestiture proceeds
    		                   0        
      proceeds from issuance of common stock and tangible equity units
    		                   0 0 0 1,219,900,000     
      debt issuance costs
    		           0 -1,000,000   -1,000,000    0 -99,300,000 -100,000 -3,100,000     
      early redemption and tender premiums paid
    		           0                
      net increase in cash, cash equivalents and restricted cash
    		               185,000,000 -127,000,000 65,000,000 9,000,000 -165,200,000 -731,200,000 184,700,000 872,000,000 24,800,000    
      cash, cash equivalents and restricted cash at january 1
    		               0 0 0 506,000,000 0 0 0 345,100,000 0 0 0 677,500,000 
      cash, cash equivalents and restricted cash at december 31
    		                           
      proceeds from site divestitures
    		                           
      other net financing transactions with lilly
    		                0 0 -11,000,000    -15,200,000  1,300,000 161,400,000 -156,400,000 
      cash and cash equivalents at september 30
    		                           
      changes in operating assets and liabilities
    		             -38,000,000 -331,000,000       215,500,000 -9,800,000  -61,800,000   
      cash and cash equivalents at june 30
    		                           
      deferred income tax benefit
    		                           
      consideration paid to lilly in connection with the separation
    		                       0 -400,000 -16,100,000 -175,100,000 
      change in deferred income taxes
    		                -5,000,000 -82,000,000 -32,000,000 35,000,000 -81,400,000 -53,300,000 -25,100,000 -14,800,000 -25,400,000 24,000,000 16,300,000 
      proceeds from settlement of net investment hedges
    		                   0 0 7,500,000 25,200,000     
      proceeds from product divestitures
    		                           
      repayments of borrowings
    		                -518,000,000 -17,000,000 -20,000,000  -306,400,000 -6,400,000 -371,400,000 -6,100,000 -50,000,000 -57,500,000 -7,500,000 
      net proceeds from revolving credit facility
    		                  50,000,000         
      cash, cash equivalents and restricted cash at september 30
    		                           
      net proceeds from sale (purchases) of property and equipment
    		                    -35,400,000       
      cash, cash equivalents and restricted cash at june 30
    		                           
      asset impairment charges
    		                  9,000,000 20,400,000 1,200,000   7,900,000 20,700,000 0 4,000,000 
      cash, cash equivalents and restricted cash at march 31
    		                  515,000,000    1,217,100,000    300,600,000 
      other net transactions with lilly
    		                           
      proceeds from issuance of common stock
    		                           
      cash, cash equivalents and restricted cash at september 30, 2019
    		                           
      net decrease in cash, cash equivalents and restricted cash
    		                         96,000,000 -376,900,000 
      other changes in operating assets and liabilities, net of acquisitions and divestitures
    		                           
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.